Multiple Sclerosis Thought Leader Panel #16 2012-05

Medpredict, May 2012, Pages: 166

BOLT / MedPredict’s Multiple Sclerosis Thought Leader Panel #16 summarizes a series of interviews conducted with our Neurology Thought leaders immediately following AAN 2012. The objective of these discussions was to highlight differential clinical advantages that are extrapolatable from the trial data that was presented.

Key areas of focus included:

- Importance of achieving a disease activity-free state
- The future role of ABCR (Interferons and Copaxone) in the era of small molecules and B-cell inhibitors.
- Efficacy and safety of S1P agonists and small molecule immunomodulators
- Natalizumab and JCV risk stratification
- Alemtuzumab
- Daclizumab
- T-cell vaccines
- IL17

Also included in the appendix of this report are compilations of BOLT/MedPredict’s Multiple Sclerosis Fantasy Formulary thought exercises from 2Q2010 and 4Q2011. These provide a time lapse picture of Thought Leader excitement for a variety of MS developmental therapeutics.

Executive Summary
- Report Hightlights

Discussion
- Disease Activity-Free State
-- RRMS
-- Progressive MS
- Interferon and Copaxone (ABCR)
-- CombiRx (Copaxone, Avonex, Combination)
-- Copaxone (glatiramer acetate; Teva)
-- Rebif (Merck-Serono/Pfizer), Avonex (Biogen), Bestaseron (Bayer)
-- PEGylated interferon beta-1a (B11BO17); Biogen
- S1P Receptor Agonists
-- Gilenya; fingolimod (Novartis)
-- siponimod (BAF-312/KRP-203; Kyorin / Novartis)
-- ONO-4641 (Ono / Merck-Serono)
-- Ponesimod ?ACT-128800 (Actelion)
- VLA-4
-- Tysabri; natalizumab (Biogen /Elan)
- Oral Immunimidulators
-- BG-12; fumarate (Biogen-Idec)
-- laquinimod (Teva)
-- teriflunomide (Sanofi-Aventis)
- B-Cell Inhibitors
-- Ocrelizumab (Roche / Biogen-Idec)
-- Ofatumumab (Genmab / GSK)
- Anti-CD-25 (Anti-IL-2)
-- DAC HYP (daclizumab; Biogen)
- CD52
-- Lemdatra / Campath; anti-CD-52; alemtuzumab (Sanofi-Aventis / Bayer-Schering)
- Vaccines / Immune Tolerance
-- Tovaxin (Opexa)
- IL17
-- seculinumab (AIN457; Novartis)

Appendix 1 - Fantasy Formulary Data 2011 and 2010
- Fantasy Formulary - Ground Rules and Scoring
- Multiple Sclerosis Fantasy Formulary Results (2011)
- Multiple Sclerosis Fantasy Formulary Results (2010)
- Data Tables
-- Table 1a: Preferred Product Classes (2011)
-- Table 1b: Preferred Product Classes (2010)
-- Table 2a: Individual Thought Leader Rankings (2011)
-- Table 2b: Individual Thought Leader Rankings (2010)
-- Table 3a: Most Frequent Favorably Mentioned Drugs (2011)
-- Table 3b: Most Frequent FavorablY Mentioned Drugs (2010)

Thought-Leader Discussions
- Interview CNSO2691
- Interview CNSO2692
- Interview CNSO2693
- Interview CNSO2694
- Interview CNSO2695
- Interview CNSO2696

- Actelion
- Bayer
- Bayer-Schering / Sanofi
- Biogen-Idec
- DAC HYP
- Biogen-Idec / Elan
- Biogen-Idec / Genentech / Roche
- GSK / Genmab
- Merck-Serono
- Merck-Serono / Pfizer
- Novartis
- Novartis / Kyorin
- Ono / Merck-Serono
- Opexa
- Roche / Actelion
- Sanofi-Aventis
- Teva / Sanofi-Aventis
- Teva

Customers who bought this item also bought

• Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011
• Thought Leader Insight & Analysis Report - Multiple Sclerosis Q2 2010
• Thought Leader Insight & Analysis Report - Rheumatology Q3 2011
• Thought Leader Insight & Analysis Report - Psoriasis Q4 2011
• Multiple Sclerosis Therapeutics - Global Strategic Business Report
• Thought Leader Insight & Analysis Report Anticoagulants Q3 2011
• Thought Leader Insight & Analysis Report - Cardiovascular Q4 2011
• Thought Leader Insight & Analysis Report - Crohn’s Disease, Ulcerative Colitis Q1 2010
• Thought Leader Insight & Analysis Report - Osteoporosis Q4 2011
• Melanoma - Thought Leader Panel 2012